Keren Shichrur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Keren Shichrur has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Nino Oniashvili
The Rina Zaizov Division of Pediatric Hematology‐Oncology Schneider Children's Medical Center Petah Tikva Israel
23 shared publications - Shai Izraeli
The Rina Zaizov Division of Pediatric Hematology‐Oncology Schneider Children's Medical Center Petah Tikva Israel
23 shared publications - Assaf Grunwald
Tel Aviv University 3 Tel Aviv
22 shared publications - Aviv Sever
Department of Pediatric Hematology/Oncology Schneider Children's Medical Center Petah Tikva Israel
22 shared publications - Dafna Gaas
Schneider Children's Medical Center 2 Petach Tikva
22 shared publications - Elena Shinderman-Maman
Schneider Children's Medical Center 2 Petach Tikva
22 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Purpose:Liquid biopsy monitoring in pediatric solid tumors is limited by low mutational burden and lack of trackable genomic drivers. We sought to develop a mutation-agnostic, methylation-based liquid biopsy framework enabling universal molecular surveillance of high-risk neuroblastoma. Experimental Design:Using whole-genome Oxford Nanopore Technologies sequencing of high-risk neuroblastoma tumors, we compared tumor-derived methylation profiles with a comprehensive atlas of normal human cell types and identified 72 neuroblastoma-specific differentially methylated regions (meNBL) that were reliably detectable in cell-free DNA (cfDNA). Marker robustness and specificity were validated using independent neuroblastoma methylation datasets and assessed against methylation profiles from other cancer types. We established neuroblastoma as a distinct methylation entity within the reference atlas by integrating a panel of 25 meNBLs, enabling quantitative estimation of tumor-derived cfDNA. Assay performance was evaluated across diagnostic, remission, relapse, and healthy control samples and compared with mutation-based and copy number–based approaches. Results:Neuroblastoma-derived cfDNA was consistently detected at diagnosis and relapse but was absent in healthy controls and during confirmed remission. Methylation-based deconvolution demonstrated high specificity, with no detectable background signal in controls, and improved performance relative to copy number–based tumor fraction estimation. Longitudinal profiling enabled early molecular detection of relapse and reliable disease monitoring. Conclusions:We establish a robust, mutation-independent methylation-based liquid biopsy strategy for neuroblastoma that enables accurate, quantitative disease monitoring across all high-risk patients, including those lacking trackable genomic alterations. This approach supports the clinical translation of methylation-based cfDNA deconvolution as a broadly applicable platform for pediatric precision oncology.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Purpose:Liquid biopsy monitoring in pediatric solid tumors is limited by low mutational burden and lack of trackable genomic drivers. We sought to develop a mutation-agnostic, methylation-based liquid biopsy framework enabling universal molecular surveillance of high-risk neuroblastoma. Experimental Design:Using whole-genome Oxford Nanopore Technologies sequencing of high-risk neuroblastoma tumors, we compared tumor-derived methylation profiles with a comprehensive atlas of normal human cell types and identified 72 neuroblastoma-specific differentially methylated regions (meNBL) that were reliably detectable in cell-free DNA (cfDNA). Marker robustness and specificity were validated using independent neuroblastoma methylation datasets and assessed against methylation profiles from other cancer types. We established neuroblastoma as a distinct methylation entity within the reference atlas by integrating a panel of 25 meNBLs, enabling quantitative estimation of tumor-derived cfDNA. Assay performance was evaluated across diagnostic, remission, relapse, and healthy control samples and compared with mutation-based and copy number–based approaches. Results:Neuroblastoma-derived cfDNA was consistently detected at diagnosis and relapse but was absent in healthy controls and during confirmed remission. Methylation-based deconvolution demonstrated high specificity, with no detectable background signal in controls, and improved performance relative to copy number–based tumor fraction estimation. Longitudinal profiling enabled early molecular detection of relapse and reliable disease monitoring. Conclusions:We establish a robust, mutation-independent methylation-based liquid biopsy strategy for neuroblastoma that enables accurate, quantitative disease monitoring across all high-risk patients, including those lacking trackable genomic alterations. This approach supports the clinical translation of methylation-based cfDNA deconvolution as a broadly applicable platform for pediatric precision oncology.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Integrated genetic and epigenetic profiling of neuroblastoma using whole-genome ONT sequencing. A, Whole-genome ONT sequencing of tumor DNA provides simultaneous genetic and epigenetic information, illustrated here for patient T6. The data enable detection of large-scale genetic alterations, shown as a CNV profile at the top, and identification of DMRs relative to control samples (bottom). Bottom, Two representative promoter-associated DMRs: the newly identified IRF6 promoter on chromosome 1 and the previously reported KRT19 promoter on chromosome 17. Individual native DNA molecules aligned to each locus are displayed, with CpG sites colored red (methylated) or blue (unmethylated). B, Oncoplot: Major genetic alterations associated with neuroblastoma were identified by whole-genome ONT sequencing and summarized across the seven sequenced tumors. The oncoplot displays clinically relevant genomic events, including gene amplifications, mutations, deletions, chromosomal copy-number aberrations, and clinical disease course annotations. C, PCA of genome-wide DNA methylation profiles from the seven neuroblastoma tumors reveals clustering according to key genomic alterations, including MYCN amplification and 11q deletion, ALK mutation, and SWI/SNF remodeling, with control samples forming a distinct cluster. D, Neuroblastoma DMR heatmap: DNA methylation data from the seven neuroblastoma tumors were compared against a reference atlas comprising methylomes from 36 healthy tissue types to identify pan-neuroblastoma–specific DMRs. Methylation levels across the 72 identified DMRs are shown in the heatmap, with colors indicating average methylation levels (red, high methylation; blue, low methylation); values represent group-level averages for each column, arranged in rows representing from top to bottom: the seven sequenced neuroblastoma tumors, PBL samples as healthy controls, public methylation data from other advanced tumor types, and previously published neuroblastoma and healthy control methylomes generated using Illumina EPIC arrays. Neuroblastoma DMRs not interrogated by the EPIC array are shown in gray. NBL, neuroblastoma.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Integrated genetic and epigenetic profiling of neuroblastoma using whole-genome ONT sequencing. A, Whole-genome ONT sequencing of tumor DNA provides simultaneous genetic and epigenetic information, illustrated here for patient T6. The data enable detection of large-scale genetic alterations, shown as a CNV profile at the top, and identification of DMRs relative to control samples (bottom). Bottom, Two representative promoter-associated DMRs: the newly identified IRF6 promoter on chromosome 1 and the previously reported KRT19 promoter on chromosome 17. Individual native DNA molecules aligned to each locus are displayed, with CpG sites colored red (methylated) or blue (unmethylated). B, Oncoplot: Major genetic alterations associated with neuroblastoma were identified by whole-genome ONT sequencing and summarized across the seven sequenced tumors. The oncoplot displays clinically relevant genomic events, including gene amplifications, mutations, deletions, chromosomal copy-number aberrations, and clinical disease course annotations. C, PCA of genome-wide DNA methylation profiles from the seven neuroblastoma tumors reveals clustering according to key genomic alterations, including MYCN amplification and 11q deletion, ALK mutation, and SWI/SNF remodeling, with control samples forming a distinct cluster. D, Neuroblastoma DMR heatmap: DNA methylation data from the seven neuroblastoma tumors were compared against a reference atlas comprising methylomes from 36 healthy tissue types to identify pan-neuroblastoma–specific DMRs. Methylation levels across the 72 identified DMRs are shown in the heatmap, with colors indicating average methylation levels (red, high methylation; blue, low methylation); values represent group-level averages for each column, arranged in rows representing from top to bottom: the seven sequenced neuroblastoma tumors, PBL samples as healthy controls, public methylation data from other advanced tumor types, and previously published neuroblastoma and healthy control methylomes generated using Illumina EPIC arrays. Neuroblastoma DMRs not interrogated by the EPIC array are shown in gray. NBL, neuroblastoma.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Neuroblastoma methylation markers enable disease monitoring and longitudinal follow-up. A, Representative CNV profiles derived from cfDNA samples collected at diagnosis from three patients with neuroblastoma with varying tumor fractions (TF%). From top to bottom, examples are shown for patients with high, intermediate, and low TF%. B, Tumor fraction (TF%) estimates obtained by methylation-based deconvolution using the 25 selected meNBL markers, shown for cfDNA samples collected at different disease stages: diagnosis (n = 11), remission (n = 6), relapse (n = 6), and healthy individuals (n = 8). Each dot represents an individual cfDNA sample, and the y-axis represents TF%. Arrows link representative TF% values in (B) to the corresponding CNV profiles shown in A. C and D, Longitudinal monitoring of neuroblastoma in two representative patients: a patient with MYCN amplification (C) and a patient without MYCN amplification (D). The x-axis denotes days from diagnosis. The left y-axis shows normalized values of established neuroblastoma disease markers, including MYCN copy number and urinary catecholamine metabolites [vanillylmandelic acid (VMA)/homovanillic acid (HVA)]. The right y-axis shows tumor fraction estimates derived from methylation-based deconvolution (NB dcn) using the neuroblastoma marker panel as well as ichorCNA. Blue shaded regions indicate time intervals during which gold-standard MIBG imaging confirmed active disease. In the MYCN-amplified case, methylation-based TF% tracking detected disease with sensitivity comparable with MYCN-based markers, whereas in the non-MYCN case, methylation-based detection mirrored imaging-based disease status.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Neuroblastoma methylation markers enable disease monitoring and longitudinal follow-up. A, Representative CNV profiles derived from cfDNA samples collected at diagnosis from three patients with neuroblastoma with varying tumor fractions (TF%). From top to bottom, examples are shown for patients with high, intermediate, and low TF%. B, Tumor fraction (TF%) estimates obtained by methylation-based deconvolution using the 25 selected meNBL markers, shown for cfDNA samples collected at different disease stages: diagnosis (n = 11), remission (n = 6), relapse (n = 6), and healthy individuals (n = 8). Each dot represents an individual cfDNA sample, and the y-axis represents TF%. Arrows link representative TF% values in (B) to the corresponding CNV profiles shown in A. C and D, Longitudinal monitoring of neuroblastoma in two representative patients: a patient with MYCN amplification (C) and a patient without MYCN amplification (D). The x-axis denotes days from diagnosis. The left y-axis shows normalized values of established neuroblastoma disease markers, including MYCN copy number and urinary catecholamine metabolites [vanillylmandelic acid (VMA)/homovanillic acid (HVA)]. The right y-axis shows tumor fraction estimates derived from methylation-based deconvolution (NB dcn) using the neuroblastoma marker panel as well as ichorCNA. Blue shaded regions indicate time intervals during which gold-standard MIBG imaging confirmed active disease. In the MYCN-amplified case, methylation-based TF% tracking detected disease with sensitivity comparable with MYCN-based markers, whereas in the non-MYCN case, methylation-based detection mirrored imaging-based disease status.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S1: Identification of neuroblastoma-specific DMRs through comparative methylome analysis to normal human cell-type atlas. Total of 152 neuroblastoma DMRs were identified in comparison to all tissue types in the human reference atlas (13). Given that neuroblastoma arises from neural crest cells, the analysis was repeated with neuronal cell types excluded from the atlas resulting in the identification of additional 36 “neuronal” regions.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S1: Identification of neuroblastoma-specific DMRs through comparative methylome analysis to normal human cell-type atlas. Total of 152 neuroblastoma DMRs were identified in comparison to all tissue types in the human reference atlas (13). Given that neuroblastoma arises from neural crest cells, the analysis was repeated with neuronal cell types excluded from the atlas resulting in the identification of additional 36 “neuronal” regions.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Detection of neuroblastoma markers in cfDNA samples. A, Heatmap showing average DNA methylation levels across the 72 identified DMRs. Rows correspond to individual meNBL markers, and columns represent cfDNA sample groups: matched cfDNA from patients with sequenced tumor tissue, cfDNA from an independent validation cohort of patients with neuroblastoma, and cfDNA from healthy individuals. Colors indicate mean methylation levels (red, high methylation; blue, low methylation). Values represent group-level averages across samples within each category. B, Tumor fraction (TF%) estimates in cfDNA for representative individuals, stratified by clinical and genomic status, using three independent approaches. Columns show TF% estimation based on (left) somatic mutation allele frequencies, applicable only to patients with identifiable tumor mutations; (middle) methylation-based deconvolution using our novel meNBL markers; and (right) CNV-based estimation using ichorCNA. Pie charts depict the relative contribution of tumor-derived cfDNA (orange-red) and nontumor cfDNA fractions. Only the methylation-based approach further resolves the nontumor fraction into cell of origin components.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Detection of neuroblastoma markers in cfDNA samples. A, Heatmap showing average DNA methylation levels across the 72 identified DMRs. Rows correspond to individual meNBL markers, and columns represent cfDNA sample groups: matched cfDNA from patients with sequenced tumor tissue, cfDNA from an independent validation cohort of patients with neuroblastoma, and cfDNA from healthy individuals. Colors indicate mean methylation levels (red, high methylation; blue, low methylation). Values represent group-level averages across samples within each category. B, Tumor fraction (TF%) estimates in cfDNA for representative individuals, stratified by clinical and genomic status, using three independent approaches. Columns show TF% estimation based on (left) somatic mutation allele frequencies, applicable only to patients with identifiable tumor mutations; (middle) methylation-based deconvolution using our novel meNBL markers; and (right) CNV-based estimation using ichorCNA. Pie charts depict the relative contribution of tumor-derived cfDNA (orange-red) and nontumor cfDNA fractions. Only the methylation-based approach further resolves the nontumor fraction into cell of origin components.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S2: Gene Ontology (GO) enrichment analysis of 152 identified DMRs. The x-axis represents the gene ratio (the proportion of genes from the methylated gene list involved in each GO term), while the size of the dots corresponds to the number of genes associated with each process. The color gradient indicates the adjusted p-value (−log10 p.adjust), reflecting the statistical significance of enrichment.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S2: Gene Ontology (GO) enrichment analysis of 152 identified DMRs. The x-axis represents the gene ratio (the proportion of genes from the methylated gene list involved in each GO term), while the size of the dots corresponds to the number of genes associated with each process. The color gradient indicates the adjusted p-value (−log10 p.adjust), reflecting the statistical significance of enrichment.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S4: Identification of neuroblastoma-specific DMRs. Total of 72 neuroblastoma DMRs were identified in comparison to all tissue types in the human reference atlas. Average methylation values across each locus in the 7 primary neuroblastoma tissues as well as PBLs are shown.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S4: Identification of neuroblastoma-specific DMRs. Total of 72 neuroblastoma DMRs were identified in comparison to all tissue types in the human reference atlas. Average methylation values across each locus in the 7 primary neuroblastoma tissues as well as PBLs are shown.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S3: DNA methylation analysis of neuroblastoma tumor samples reveals distinct methylation patterns. (A) Genome-wide DNA methylation levels were calculated in 7 neuroblastoma tumor gDNA and 3 PBL pools of 10 individuals each revealed globally reduced levels in neuroblastoma. Analysis is represented by violin plots with orange and white dots drawn at the distribution medians and means respectively. (B) Hierarchical clustering analysis based on methylation levels in neuroblastoma tumor and PBL pool samples reveal distinct molecular characteristics.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S3: DNA methylation analysis of neuroblastoma tumor samples reveals distinct methylation patterns. (A) Genome-wide DNA methylation levels were calculated in 7 neuroblastoma tumor gDNA and 3 PBL pools of 10 individuals each revealed globally reduced levels in neuroblastoma. Analysis is represented by violin plots with orange and white dots drawn at the distribution medians and means respectively. (B) Hierarchical clustering analysis based on methylation levels in neuroblastoma tumor and PBL pool samples reveal distinct molecular characteristics.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Table S1. Clinical and Genomic Characteristics of Neuroblastoma Tumor Samples Sequenced by ONT
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Table S1. Clinical and Genomic Characteristics of Neuroblastoma Tumor Samples Sequenced by ONT
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S5: Target distribution of 72 meNBLs across various genomic regions.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
Supplementary Figure S5: Target distribution of 72 meNBLs across various genomic regions.